ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 23 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $949,503 | -20.5% | 82,926 | -28.6% | 0.00% | -100.0% |
| Q2 2023 | $1,194,279 | +17.3% | 116,175 | +21.0% | 0.00% | 0.0% |
| Q1 2021 | $1,018,000 | +76.4% | 96,017 | +109.8% | 0.00% | – |
| Q4 2020 | $577,000 | +42.5% | 45,771 | -0.6% | 0.00% | – |
| Q3 2020 | $405,000 | +495.6% | 46,058 | +330.7% | 0.00% | – |
| Q3 2018 | $68,000 | -38.2% | 10,694 | -22.0% | 0.00% | – |
| Q1 2018 | $110,000 | -46.3% | 13,705 | -25.0% | 0.00% | – |
| Q4 2017 | $205,000 | – | 18,272 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |